Latest & greatest articles for rosuvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rosuvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rosuvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rosuvastatin

21. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets

Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets 20487050 2010 07 20 2011 11 10 2015 11 19 1742-1241 64 8 2010 Jul International journal of clinical practice Int. J. Clin. Pract. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised (...) randomised to ezetimibe/simvastatin 10/40 mg (as a combination tablet; n = 261), atorvastatin 40 mg (n = 263) or rosuvastatin 5 mg (n = 73) or 10 mg (n = 189) once daily for 6 weeks. Rosuvastatin dose was based on UK prescribing instructions. The primary outcome measure was the proportion of patients achieving LDL-C < 2 mmol/l at the end of the study. The percentage of patients (adjusted for baseline differences) achieving LDL-C < 2 mmol/l was 69.4% with ezetimibe/simvastatin 10/40 mg, compared with 33.5

EvidenceUpdates2010

22. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia

Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia 20223367 2010 03 12 2010 04 12 2015 11 19 1558-3597 55 11 2010 Mar 16 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. 1121-6 10.1016/j.jacc.2009.10.042 This study was undertaken to evaluate the efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia (...) by a 40-week open-label, titration-to-goal extension phase in 177 pubertal children, ages 10 to 17 years, with familial hypercholesterolemia. Participants were randomly assigned to placebo or rosuvastatin 5, 10, or 20 mg once daily. Compared with placebo, rosuvastatin 5, 10, and 20 mg reduced LDL-C by 38%, 45%, and 50%, respectively (p < 0.001 for each group vs. placebo). With a maximum allowed dose of 20 mg, 40% achieved the treatment goal of <110 mg/dl during the open-label, titration-to-goal phase

EvidenceUpdates2010

23. Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. Population Insights From the ARIC (Atherosclerosis Risk in Communities) Study

Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. Population Insights From the ARIC (Atherosclerosis Risk in Communities) Study 20082929 2010 01 19 2010 03 04 2016 12 15 1558-3597 54 25 2009 Dec 15 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (...) ) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. 2388-95 10.1016/j.jacc.2009.10.006 The purpose of this study is to describe the proportion of "JUPITER-eligible" (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) individuals and clinical outcomes of individuals based on high-sensitivity C-reactive protein (hs-CRP) and low-density lipoprotein cholesterol (LDL-C) strata in the ARIC (Atherosclerosis Risk

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

24. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER)

Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER) 20102893 2010 01 27 2010 03 04 2015 11 19 1879-1913 105 1 2010 Jan 01 The American journal of cardiology Am. J. Cardiol. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). 69-76 10.1016/j.amjcard.2009.08.651 (...) Statins are the most commonly prescribed agents for lowering levels of low-density lipoprotein (LDL) cholesterol. Although dose-dependent reductions in levels of atherogenic lipids are observed with all statins, the impact of increasing dose has not been fully elucidated. An individual patient data pooled analysis was performed of 32,258 patients in studies comparing the efficacy of rosuvastatin with that of atorvastatin or simvastatin. The impact of increasing dose on lowering LDL cholesterol

EvidenceUpdates2010

25. Comparison of sequential rosuvastatin doses in hypercholesterolaemia: a meta-analysis of randomised controlled trials

Comparison of sequential rosuvastatin doses in hypercholesterolaemia: a meta-analysis of randomised controlled trials Comparison of sequential rosuvastatin doses in hypercholesterolaemia: a meta-analysis of randomised controlled trials Comparison of sequential rosuvastatin doses in hypercholesterolaemia: a meta-analysis of randomised controlled trials Gray J, Edwards SJ, Lip GY CRD summary This review provided evidence for improved efficacy, as assessed by surrogate markers, in treating (...) patients with hypercholesterolaemia with each sequential titration of rosuvastatin and a generally consistent tolerability profile across the dose range. The authors' conclusions reflect the evidence presented, but the lack of validity assessment and lack of reporting of some data made the reliability of the conclusions uncertain. Authors' objectives To quantify the benefits and risks associated with sequential rosuvastatin titrations across dosage range for the treatment of patients

DARE.2010

26. JUPITER randomised controlled trial: Rosuvastatin is similarly effective for primary prevention of cardiovascular disease in women as in men

JUPITER randomised controlled trial: Rosuvastatin is similarly effective for primary prevention of cardiovascular disease in women as in men Rosuvastatin is similarly effective for primary prevention of cardiovascular disease in women as in men | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Rosuvastatin is similarly effective for primary prevention of cardiovascular disease in women as in men Article Text Therapeutics JUPITER randomised controlled trial Rosuvastatin is similarly effective for primary prevention of cardiovascular disease in women

Evidence-Based Medicine (Requires free registration)2010

27. Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein

Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein MacDonald (...) GP Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of rosuvastatin for the primary prevention of cardiovascular events in patients with different Framingham Risk Scores (FRSs

NHS Economic Evaluation Database.2010

28. An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial

An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial Lorgelly PK, Briggs AH, Wedel H, Dunselman P, Hjalmarson A, Kjekshus J, Waagstein F, Wikstrand J, Janosi A, van Veldhuisen DJ, Barrios V, Fonseca C, McMurray JJ, the Controlled (...) Rosuvastatin Multinational Study in Heart Failure Study Group Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of rosuvastatin in patients aged 60 years or older, with systolic heart failure, of

NHS Economic Evaluation Database.2010

29. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial

Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial 19717850 2009 10 02 2010 07 14 2015 11 19 1522-9645 30 19 2009 Oct European heart journal Eur. Heart J. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. 2327-36 10.1093/eurheartj/ehp357 This ancillary analysis of the GISSI-HF database aims at assessing the effect of rosuvastatin on the occurrence of atrial fibrillation (AF) in patients (...) with chronic heart failure (HF) who were not in AF at study entry. GISSI-HF was a double-blind, placebo-controlled trial testing n-3 PUFA and rosuvastatin vs. corresponding placebos in patients with chronic HF. Atrial fibrillation occurrence was defined as the presence of AF in the electrocardiogram (ECG) performed at each visit during the trial or AF as a cause of worsening HF or hospital admission or as an event during hospitalization. Among the 3690 patients (80.7%) without AF on their baseline ECG

EvidenceUpdates2009

30. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event

Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event 19195498 2009 02 06 2009 03 19 2016 12 15 1879-1913 103 4 2009 Feb 15 The American journal of cardiology Am. J. Cardiol. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. 437-41 10.1016/j.amjcard.2008.10.008 In addition to inhibiting (...) to inhibit ROCK activity. Accordingly, we enrolled 30 men with stable atherosclerosis (low-density lipoprotein [LDL] > or =100 mg/dL) in a randomized, double-blind study comparing equivalent LDL-lowering doses of a hydrophilic statin (rosuvastatin 10 mg once a day) with a lipophilic statin (atorvastatin 40 mg once a day) for 28 days. We assessed the change in lipids, ROCK activity, and flow-mediated dilation (FMD) of the brachial artery before and after statin therapy. Both treatment groups exhibited

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

31. Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice

Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice Gandhi SK, Jarbrink K, Fox KM, Brandrup-Wognsen G CRD summary This review concluded that compared with other statins there was strong and consistent evidence (...) to demonstrate the effectiveness of rosuvastatin in reducing low-density lipoprotein cholesterol (LDL-C) and LDL-C goals in usual care settings. These conclusions should be interpreted with caution given a possibility of publication bias, insufficient data and limited methodological rigour of the included studies. Authors' objectives To assess the effectiveness of rosuvastatin for the treatment of hypercholesterolaemia in the usual-care setting. Searching MEDLINE and EMBASE were searched from January 2003

DARE.2009

32. Rosuvastatin prevented major cardiovascular events in people with elevated C-reactive protein

Rosuvastatin prevented major cardiovascular events in people with elevated C-reactive protein Rosuvastatin prevented major cardiovascular events in people with elevated C-reactive protein | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Rosuvastatin prevented major cardiovascular events in people with elevated C-reactive protein Article Text Therapeutics Rosuvastatin prevented major cardiovascular events in people with elevated C-reactive protein Statistics from Altmetric.com No Altmetric data available for this article. P M Ridker Dr P M Ridker, Brigham

Evidence-Based Medicine (Requires free registration)2009

33. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials

Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials 19064019 2008 12 09 2008 12 18 2015 11 19 1879-1913 102 12 2008 Dec 15 The American journal of cardiology Am. J. Cardiol. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. 1654-62 10.1016/j.amjcard.2008.08.014 The benefit from statin therapy is proportional (...) to the low-density lipoprotein (LDL) cholesterol reduction. However, adverse events appear to be related to dose rather than LDL cholesterol reduction. Although serious side effects are rare, any comparison of statins requires scrutiny of the relation between therapeutic effect and risk of side effects. This report sought to determine whether the additional LDL cholesterol lowering with rosuvastatin over atorvastatin could be obtained without increased risk of short-term adverse events. Twenty-five studies (approximately

EvidenceUpdates2009

34. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. 19329177 2009 04 06 2009 04 17 2015 11 19 1474-547X 373 9670 2009 Apr 04 Lancet (London, England) Lancet Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. 1175-82 10.1016/S0140-6736(09)60447-5 Statins lower high-sensitivity (...) trial (87% of full cohort), we prospectively assessed the effects of rosuvastatin 20 mg versus placebo on rates of non-fatal myocardial infarction, non-fatal stroke, admission for unstable angina, arterial revascularisation, or cardiovascular death (prespecified endpoints) during a maximum follow-up of 5 years (median 1.9 years), according to on-treatment concentrations of LDL cholesterol (>/=1.8 mmol/L or <1.8 mmol/L) and hsCRP (>/=2 mg/L or <2 mg/L). We included all events occurring after

Lancet2009

35. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. 19332456 2009 04 02 2009 04 08 2015 11 19 1533-4406 360 14 2009 Apr 02 The New England journal of medicine N. Engl. J. Med. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. 1395-407 10.1056/NEJMoa0810177 Statins reduce the incidence of cardiovascular events in patients at high cardiovascular risk. However, a benefit of statins in such patients who are undergoing hemodialysis has not been (...) proved. We conducted an international, multicenter, randomized, double-blind, prospective trial involving 2776 patients, 50 to 80 years of age, who were undergoing maintenance hemodialysis. We randomly assigned patients to receive rosuvastatin, 10 mg daily, or placebo. The combined primary end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary end points included death from all causes and individual cardiac and vascular events. After 3 months

NEJM2009

36. A randomized trial of rosuvastatin in the prevention of venous thromboembolism.

A randomized trial of rosuvastatin in the prevention of venous thromboembolism. 19329822 2009 04 30 2009 05 07 2016 12 15 1533-4406 360 18 2009 Apr 30 The New England journal of medicine N. Engl. J. Med. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. 1851-61 10.1056/NEJMoa0900241 Controversy persists regarding the extent of shared pathways between arterial and venous thrombosis and whether treatments of known efficacy for one disease process have consistent (...) benefits for the other. Observational studies have yielded variable estimates of the effect of statin therapy on the risk of venous thromboembolism, and evidence from randomized trials is lacking. We randomly assigned 17,802 apparently healthy men and women with both low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher to receive rosuvastatin, 20 mg per day, or placebo. We

NEJM2009 Full Text: Link to full Text with Trip Pro

37. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of rosuvastatin in comparison with atorvastatin, simvastatin, and pravastatin for managing lipid parameters in patients with hypercholesterolaemia. The authors

NHS Economic Evaluation Database.2008

38. Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal

Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal Pinto C G, Carrageta M O, Miguel L S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the clinical and economic impact of rosuvastatin (ROS) versus other statins in the treatment of hypercholesterolaemia and prevention of ischaemic heart disease, in untreated individuals over 35 years of age with previously untreated hypercholesterolaemia. The authors concluded that ROS was a cost-effective strategy in the Portuguese setting. The study

NHS Economic Evaluation Database.2008

39. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. 18757089 2008 12 19 2009 01 06 2016 03 09 1474-547X 372 9645 2008 Oct 04 Lancet (London, England) Lancet Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. 1231-9 10.1016/S0140-6736(08)61240-4 Large observational studies, small prospective studies and post-hoc analyses (...) of randomised clinical trials have suggested that statins could be beneficial in patients with chronic heart failure. However, previous studies have been methodologically weak. We investigated the efficacy and safety of the statin rosuvastatin in patients with heart failure. We undertook a randomised, double-blind, placebo-controlled trial in 326 cardiology and 31 internal medicine centres in Italy. We enrolled patients aged 18 years or older with chronic heart failure of New York Heart Association class II-IV

Lancet2008

40. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. 18997196 2008 11 21 2008 11 25 2016 08 03 1533-4406 359 21 2008 Nov 20 The New England journal of medicine N. Engl. J. Med. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. 2195-207 10.1056/NEJMoa0807646 Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity (...) C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment. We randomly assigned 17,802 apparently healthy men and women with low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher to rosuvastatin, 20 mg daily, or placebo and followed them for the occurrence

NEJM2008